Conclusions: In comparison to laser photocoagulation, anti-VEGF monotherapy appears to yield lower levels of myopia and anisometropia; however, the incidence of hypermetropia and astigmatism is variable among cohort groups treated with different anti-VEGF agents. The gene discussed is VEGFA; the disease is Hypermetropia.